68Ga-NODAGA-RGD is a suitable substitute for 18F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process

Nuclear Medicine and Biology

Volumn 39, Issue 6, 2012, Pages 777-784

  Pohle, Karolin ^a   Notni, Johannes ^b   Bussemer, Johanna ^a   Kessler, Horst ^b,c   Schwaiger, Markus ^a   Beer, Ambros J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

3 integrin; 68Ga NODAGA RGD; Gallium 68; Positron emission tomography; RGD peptides

Indexed keywords

4 (2 HYDROXYETHYL) 1 PIPERAZINEETHANESULFONIC ACID; DRUG METABOLITE; ECHISTATIN I 125; GALACTOCYCLO(RGDFK) F 18; GALLIUM 68; NODAGA RGD GA 98; TIN OXIDE; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; 68GA NODAGA RGD; 68GA-NODAGA-RGD; COORDINATION COMPOUND; CYCLOPEPTIDE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUOROGALACTO RGD; FLUOROGALACTO-RGD; GALACTOSE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOMATION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG MANUFACTURE; DRUG STABILITY; DRUG TUMOR LEVEL; DRUG URINE LEVEL; FEMALE; GALLBLADDER; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; HYDROPHILICITY; IC 50; IN VIVO STUDY; INTESTINE; ISOTOPE LABELING; MELANOMA; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; METABOLISM; METHODOLOGY; QUALITY CONTROL; RADIOCHEMISTRY; TUMOR CELL LINE;

ANIMALS; AUTOMATION; CELL LINE, TUMOR; COORDINATION COMPLEXES; FEMALE; GALACTOSE; HUMANS; ISOTOPE LABELING; MICE; PEPTIDES, CYCLIC; POSITRON-EMISSION TOMOGRAPHY; QUALITY CONTROL; RADIOACTIVE TRACERS; RADIOCHEMISTRY; RADIOPHARMACEUTICALS;

EID: 84863990736     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.02.006     Document Type: Article

References (25)

1. Haubner R., Wester H.J., Burkhart F., et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001, 42:326-336.
2. 18F-labelled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001, 61:1781-1785.
3. 3-integrin expression in vivo. Acc Chem Res 2009, 42:969-980.
4. 18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjugate Chem 2004, 15:61-69.
5. 18F]Galacto-RGD. PLoS Med 2005, 2:e70.
6. 18F-Galacto-RGD, a new radiotracer for imaging αvβ3 expression. J Nucl Med 2006, 47:763-769.
7. 68Ga. Eur J Nucl Med Mol Imaging 2005, 32:478-485.
8. 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imaging 2008, 3:67-77.
9. 68Ga-labeled peptide. Nucl Med Biol 2008, 35:529-536.
10. 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med 2008, 49:830-836.
11. 68Ga-NODAGA-RGD for imaging αvβ3 integrin expression. Eur J Nucl Med Mol Imaging 2011, 38:1303-1312.
12. 68Ga-NODAGA-RGDyK for αvβ3 integrin PET imaging. Preclinical investigation and dosimetry. Nuklearmedizin 2011, 50:225-233.
13. 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours?. Eur J Nucl Med Mol Imaging 2011, 38:2005-2013.
14. Notni J., Šimeček J., Hermann P., Wester H.J. TRAP, a powerful and versatile framework for gallium-68 radiopharmaceuticals. Chem Eur J 2011, 17:14718-14722.
15. 68Ga-Based PET-radiopharmaceuticals at room temperature. Bioconjugate Chem 2008, 19:569-573.
16. Breeman W.A.P., Kwekkeboom D.J., Kooij P.P.M., et al. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med 1995, 36:623-627.
17. de Jong M., Breeman W.A.P., Bernard B.F., et al. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0,TYR3]octreotide is dependent on the peptide amount. Eur J Nucl Med 1999, 26:693-698.
18. Velikyan I., Sundin A., Eriksson B., et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours - impact of peptide mass. Nucl Med Biol 2010, 37:265-275.
19. 68Ga generator eluates for labeling of biomolecules via bifunctional chelators. J Label Compd Radiopharm 2005, 48:S188.
20. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 2004, 31:1097-1104.
21. 68Ga-Dotatoc for clinical application. Nucl Med Commun 2010, 31:753-758.
22. 68Ga-labeled peptide solutions. J Radioanal Nucl Chem 2010, 283:753-756.
23. Theodore T.R., Van Zandt R.L., Carpenter R.H. Pilot ascending dose tolerance study of parenterally administered 4-(2-Hydroxyethyl)-1-piperazine ethane sulfonic acid (TVZ-7) in dogs. Cancer Biother Radiopharm 1997, 12:345-349.
24. Theodore T.R., Van Zandt R.L., Carpenter R.H. Preliminary evaluation of a fixed dose of zwitterionic piperazine (TVZ-7) in clinical cancer. Cancer Biother Radiopharm 1997, 12:351-353.
25. Sánchez-Crespo A., Andreo P., Larsson S.A. Positron flight in human tissues and its influence on PET image spatial resolution. Eur J Nucl Med Mol Imaging 2004, 31:44-51.